Expertise in
14
conditions

Toshimitsu Fujii

Tokyo, JP 
Expertise in
14
conditions
Tokyo, JP 

Overview

Toshimitsu Fujii practices practicing medicine in Tokyo, Japan.

Fujii is highly rated in 14 conditions, according to our data. Their clinical expertise encompasses Viral Gastroenteritis, Crohn's Disease, Hemorrhagic Proctocolitis, Endoscopy, and Colonoscopy.

They are actively involved in clinical research, co-authoring 99 peer reviewed articles and participating in 6 clinical trials.

Locations

Tokyo, Japan
Other Locations
Yushima, 1138519, Japan
Soka, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
View 5 Less Clinical Trials

99 Total Publications

Data-driven subphenotyping uncovers ulcerative colitis subtype with high risk for relapse in Japan: a prospective multicenter cohort study.
Data-driven subphenotyping uncovers ulcerative colitis subtype with high risk for relapse in Japan: a prospective multicenter cohort study.
Journal: The Lancet regional health. Western Pacific
Published: June 03, 2026

Frequently Asked Questions about Toshimitsu Fujii

Is Toshimitsu Fujii a top-rated expert for Viral Gastroenteritis?

MediFind is an objective health platform that identifies experts based on real-world data. Toshimitsu Fujii is classified as an Elite expert for Viral Gastroenteritis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Toshimitsu Fujii participate in research or clinical trials?

Yes. Toshimitsu Fujii has published 99 articles and abstracts on conditions like Viral Gastroenteritis. You can view a list of Toshimitsu Fujii's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Fujii's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 8 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile